Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments

Testimony of John F. Crowley President and CEO,…

Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…

Learn more

CSBA Letter to Congressional Leaders on PBM, PPRV…

Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…

Learn more

BIO's Comments on Advisory Committee on…

Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…

Learn more

Letter to the Honorable John Carey

March 10, 2016

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx

March 10, 2016

Frequently Asked Questions Document

Letter to Governor Deval Patrick

March 10, 2016

BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

BIO Testimony regarding Oregan Senate Bill 570

March 10, 2016

Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.

Clinical Trials: ICTRP guidelines

March 10, 2016

BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…

Clinical Trials: Review of the Declaration of Helsinki

March 10, 2016

BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.

Request for Comment Extension RE: Docket No. APHIS-2014-0054 – Environmental Impact Statement; Introduction of the Products of Biotechnology

February 18, 2016

We, the undersigned organizations, appreciate the opportunity to provide comment on APHIS’ Notice of Intent (NOI) to prepare an environmental impact statement in connection with potential changes to APHIS biotechnology regulations (7 CFR 340). Our…

BIO 2016 Special 301 Submission

February 8, 2016

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission.

BIO Comments on FDA voluntary labeling of GE salmon

January 26, 2016

Food and Drug Administration Docket No. FDA-2015-D-4272; Food Labeling; Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon; Draft Guidance for Industry.

Congressional Black Caucus Letter to EPA on RFS RVO

October 30, 2015

As you finalize the proposed rules under the Renewable Fuel Standard, we respectfully urge you to not reduce the biofuels volume requirements. The RFS program has helped the environment, our economy, and has increased our confidence in renewable…